Adicet Bio ACET

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.05 (-5.44%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Adicet Bio (ACET)
    Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.7961

    • Market Cap

      $65.60 Million

    • Price-Earnings Ratio

      -0.60

    • Total Outstanding Shares

      82.40 Million Shares

    • Total Employees

      143

    • Dividend

      No dividend

    • IPO Date

      September 16, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      131 dartmouth street, Boston, MA, 02116

    • Homepage

      https://www.adicetbio.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow$-100.31 Million
    Net Cash Flow From Operating Activities$-92.38 Million
    Net Cash Flow From Operating Activities, Continuing$-92.38 Million
    Net Cash Flow, Continuing$-100.31 Million
    Net Cash Flow From Financing Activities, Continuing$111.31 Million
    Net Cash Flow From Financing Activities$111.31 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Operating Expenses$21.82 Million
    Revenues$0
    Operating Income/Loss$-127.61 Million
    Net Income/Loss Available To Common Stockholders, Basic$-117.12 Million
    Operating Expenses$127.61 Million
    Diluted Earnings Per Share$-1.33

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-117.11 Million
    Other Comprehensive Income/Loss$16,000
    Comprehensive Income/Loss Attributable To Parent$-117.11 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Current Liabilities$19.39 Million
    Equity Attributable To Parent$186.61 Million
    Assets$220.22 Million
    Liabilities$33.61 Million
    Fixed Assets$22.52 Million
    Noncurrent Assets$40.08 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ACET from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.